Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 5:38 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 3,754 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Phase duration Clear all
Terminated Phase 4 Interventional Results available

Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain

NCT02101554
View directory record Official record
Conditions
Moderate-severe Pain
Interventions
Ages 7-11, ages 12-17
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
19
States / cities
Irvine, California • Los Angeles, California • Orange, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2020 · Synced Nov 2, 2026, 5:38 AM EST
Completed Phase 2 Interventional Results available

A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma

NCT00639002
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ruxolitinib 25 mg, Dexamethasone 40 mg
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Highland, California • Boynton Beach, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Nov 2, 2026, 5:38 AM EST
Completed Phase 2 Interventional Results available

Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

NCT00492401
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
decitabine, laboratory biomarker analysis, pharmacological study, high performance liquid chromatography, microarray analysis, RNA analysis, mass spectrometry, DNA methylation analysis, matrix-assisted laser desorption/ionization time of flight mass spectrometry
Drug · Other · Genetic
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Nov 2, 2026, 5:38 AM EST
Active, not recruiting Not applicable Interventional

Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy

NCT01829958
View directory record Official record
Conditions
Non Hodgkin Lymphoma (NHL), Diffuse Large B-cell Lymphoma (DLBCL)
Interventions
rituximab, prednisone, Geriatric Assessment
Drug · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Nov 2, 2026, 5:38 AM EST
Terminated Phase 3 Interventional Results available

Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

NCT01012297
View directory record Official record
Conditions
Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Corpus Leiomyosarcoma
Interventions
Bevacizumab, Docetaxel, Filgrastim, Gemcitabine Hydrochloride, Pegfilgrastim, Placebo
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
201
States / cities
Phoenix, Arizona • Burbank, California • Concord, California + 138 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Nov 2, 2026, 5:38 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

NCT05230810
View directory record Official record
Conditions
HER2-positive Metastatic Breast Cancer
Interventions
Alpelisib, Tucatinib, Fulvestrant
Drug
Lead sponsor
Criterium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Aurora, Colorado • Fort Collins, Colorado • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Nov 2, 2026, 5:38 AM EST
Terminated Phase 2 Interventional

Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

NCT00801060
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Lumiliximab + FCR, FCR
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
9
States / cities
Gainesville, Florida • Miami, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Nov 2, 2026, 5:38 AM EST
Active, not recruiting Not applicable Interventional

Flashed Light Therapy for Adolescents With ADHD and Delayed Sleep Timing

NCT06036420
View directory record Official record
Conditions
ADHD
Interventions
Flashed Light Therapy, Videoconference-delivered Cognitive Behavioral Therapy
Device · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
14 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Nov 2, 2026, 5:38 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Multiple Ascending Dose Study of TMP-301 in Healthy Subjects

NCT06025396
View directory record Official record
Conditions
Cocaine Use Disorder, Substance Use Disorders, Healthy Volunteers
Interventions
Cohort 1 - TMP-301, Placebo, Cohort 2 - TMP-301, Cohort 3 - TMP-301, Cohort 4 - TMP-301
Drug
Lead sponsor
Tempero Bio, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Nov 2, 2026, 5:38 AM EST
Active, not recruiting Phase 1Phase 2 Interventional Results available

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

NCT04345913
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib Hydrochloride, Eribulin Mesylate, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
43
States / cities
Sacramento, California • Derby, Connecticut • Fairfield, Connecticut + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 2, 2026, 5:38 AM EST
Not yet recruiting Phase 2 Interventional

TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

NCT07502872
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Lymphoma, Lymphoma, B-Cell
Interventions
Tafasitamab, Polatuzumab vedotin, Glofitamab, Obinutuzumab
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 2, 2026, 5:38 AM EST
Active, not recruiting Phase 1 Interventional

Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors

NCT03889795
View directory record Official record
Conditions
Advanced Pancreatic Cancer, Advanced Solid Tumor
Interventions
Metformin, Simvastatin, Digoxin
Drug
Lead sponsor
Danae Hamouda, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Nov 2, 2026, 5:38 AM EST
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

NCT00175877
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
19
States / cities
Huntsville, Alabama • San Diego, California • Danbury, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Nov 2, 2026, 5:38 AM EST
Completed Phase 2 Interventional

High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia

NCT00002865
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, mesna, methotrexate, therapeutic hydrocortisone, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
Biological · Drug · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Nov 2, 2026, 5:38 AM EST
Terminated Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

NCT05660265
View directory record Official record
Conditions
Hematologic Diseases, Anaemia, Sickle Cell
Interventions
GSK4172239D, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Miami, Florida • Tamarac, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Nov 2, 2026, 5:38 AM EST
Recruiting Phase 3 Interventional

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens

NCT06127407
View directory record Official record
Conditions
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Interventions
Ivosidenib 500mg, Placebo
Drug
Lead sponsor
Servier Bio-Innovation LLC
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
22
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 2, 2026, 5:38 AM EST
Completed Phase 1 Interventional

Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management

NCT02199236
View directory record Official record
Conditions
Rectal or Anal Cancer
Interventions
endorectal brachytherapy, concurrent capecitabine or 5-FU, Questionnaires
Radiation · Drug · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Nov 2, 2026, 5:38 AM EST
Completed No phase listed Observational

VeClose Five Year Follow-Up Extension Study

NCT03455699
View directory record Official record
Conditions
Great Saphenous Vein (GSV) With Venous Reflux Disease
Interventions
VenaSeal SCS, ClosureFast Radiofrequency Ablation (RFA), Roll-In (VenaSeal SCS)
Device
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
21 Years to 70 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Scottsdale, Arizona • San Diego, California • Greenwood Village, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Nov 2, 2026, 5:38 AM EST
Completed Not applicable Interventional

SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer

NCT02562027
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell-Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
Interventions
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13, Modified Medical Research Council, EQ-5D, Center for Epidemiological Studies Depression Scale, Medical Outcomes Study Social Support Survey
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Nov 2, 2026, 5:38 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics

NCT04226131
View directory record Official record
Conditions
Rheumatoid Arthritis, Healthy Controls
Interventions
Blood Draw, Disease Activity (DAS-28) Assessment, Skeletal Muscle Mitochondrial Respiratory Capacity, Muscle Biopsy, Body Composition, Cardiopulmonary Exercise Test (CPET), Strength Testing, Questionnaires, Skeletal Muscle Biomechanical Property Assessment
Other
Lead sponsor
Duke University
Other
Eligibility
25 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Nov 2, 2026, 5:38 AM EST
Terminated Phase 1 Interventional

Hemophilia B Gene Therapy With AAV8 Vector

NCT01620801
View directory record Official record
Conditions
Hemophilia B
Interventions
AAV8-hFIX19
Biological
Lead sponsor
Spark Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Nov 2, 2026, 5:38 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants

NCT03649165
View directory record Official record
Conditions
Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Healthy Participants
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Acetaminophen
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Nov 2, 2026, 5:38 AM EST
Not listed Not applicable Interventional

Immune Effects in Patients Treated With Whole Breast Irradiation

NCT03567044
View directory record Official record
Conditions
Breast Cancer
Interventions
Blood Draw
Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
45 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Nov 2, 2026, 5:38 AM EST
Active, not recruiting Phase 2 Interventional

Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer

NCT06660407
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Immunotherapy, Palliative Radiation Therapy, Spatially-fractionated Radiation Therapy
Procedure · Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 2, 2026, 5:38 AM EST